Status:
WITHDRAWN
A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
Lead Sponsor:
Winthrop University Hospital
Conditions:
Proteinuric Renal Disease
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression an...
Detailed Description
Objectives: 1. To determine the effect of oral paricalcitol on protein excretion in patients with proteinuric renal diseases 2. To determine the effect of oral paricalcitol on renal disease progressi...
Eligibility Criteria
Inclusion
- Stable chronic kidney disease
- Urine protein : Creatinine ratio \> 0.4
- Chronic kidney disease stage 2-4 with eGFR 15-90 ml/min
- PTH (intact) \>20 pg/ml and \<250 pg/ml
- Age 18-85
- If on ACEI/ARB, then dose optimized (BP, K)
Exclusion
- Failure to provide informed consent
- Glomerunephritis requiring active treatment with immunosuppresive therapy
- Serum phosphorus \> 5.2
- Serum calcium (adjusted for albumin)\> 10.0
- Active malignancy
- Likelihood of requiring renal replacement therapy within 1 year
- Uncontrolled hypertension
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00469625
Start Date
July 1 2006
End Date
January 1 2008
Last Update
December 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Winthrop Univ. Hospital
Mineola, New York, United States, 11501